Demcizumab
| Monoclonal antibody | |
|---|---|
| Type | ? |
| Source | Humanized (from mouse) |
| Target | DLL4 |
| Identifiers | |
| CAS Number | 1243262-17-0 |
| ATC code | None |
| IUPHAR/BPS | 8451 |
| ChemSpider | none |
| Chemical data | |
| Formula | C6444H10004N1700O2028S52 |
| Molar mass | 145.3 kg/mol |
Demcizumab /dɛmˈsɪzᵿmæb/ is a humanized monoclonal antibody designed for the treatment of cancer.[1]
As of 2015, the drug is being developed by OncoMed Pharmaceuticals in non-small-cell lung cancer as well as pancreatic cancer, in collaboration with Celgene.
Mechanism of action
Demcizumab blocks Delta-like ligand 4 (DLL4), a ligand of Notch receptors. Notch signaling has been implicated as a key signaling pathway in cancer stem cells. By treating patients with a combination of Demcizumab and a cytotoxic chemotherapy, it is hoped that a more durable anti-tumor response can be achieved than with chemotherapy alone.
References
- ↑ "Statement on a nonproprietary name adopted by the USAN Council" (PDF). AMA. N12/07. Retrieved 1 Dec 2014.(registration required)
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
This article is issued from Wikipedia - version of the Sunday, February 28, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.